97) cal modalities for achieving HIV epidemic control. |
98) ll need in terms of treatment and disease control. |
99) ce allocation, education, management, and control. |
100) lating immune cells is critical for tumor control. |
101) onsibility and desirably within one's own control. |
102) with PEG(SH)2 was also investigated as a control. |
103) rous fibroblast cells (CCL-210) used as a control. |
104) using the right carotid artery (RCA) as a control. |
105) reated with MyD88 inhibitor compared with control. |
106) a epidemics continue to challenge disease control. |
107) the HIV positive group than the negative control. |
108) onist, on signal transduction and glucose control. |
109) 01) of ESCC patients compared with normal control. |
110) te, all-out cycling test: foam rolling or control. |
111) , stress responses, and immune checkpoint control. |
112) d 51.2 mg L-1 nZVIs compared to untreated control. |
113) ade inflammation despite robust virologic control. |
114) ional systems that rely on constant human control. |
115) study social touch, self-touch, and motor control. |
116) ed solely to repetition or reduced visual control. |
117) al lineage contributes to the myelination control. |
118) been made in the past decade towards its control. |
119) l and has proven difficult to predict and control. |
120) ained exposed to s-flow to be used as the control. |
121) than one-third have their condition under control. |
122) function blocking antibody or its isotype control. |
123) ncreased after noise exposure compared to control. |
124) ulation for targeted, light-based readout/control. |
125) neurogenetic aspects of behavioural self-control. |
126) ined by Health Canada/Centers for Disease Control and Prevention (CDC)-associated wi |
127) tation into practice (Centers for Disease Control and Prevention Tier 1 applications |
128) identified using the Centers for Disease Control and Prevention algorithm of 21 Int |
129) uidelines of American Centers for Disease Control and Prevention, Diagnostic Criteri |
|